These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 15717944)
1. G250: a carbonic anhydrase IX monoclonal antibody. Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944 [TBL] [Abstract][Full Text] [Related]
2. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Mulders P; Bleumer I; Debruyne F; Oosterwijk E Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181 [No Abstract] [Full Text] [Related]
3. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model. Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982 [TBL] [Abstract][Full Text] [Related]
4. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948 [TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068 [TBL] [Abstract][Full Text] [Related]
6. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742 [TBL] [Abstract][Full Text] [Related]
7. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076 [TBL] [Abstract][Full Text] [Related]
8. Targeting of adenovirus to human renal cell carcinoma cells. Jongmans W; van den Oudenalder K; Tiemessen DM; Molkenboer J; Willemsen R; Mulders PF; Oosterwijk E Urology; 2003 Sep; 62(3):559-65. PubMed ID: 12946777 [TBL] [Abstract][Full Text] [Related]
9. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. Oosterwijk E; Debruyne FM World J Urol; 1995; 13(3):186-90. PubMed ID: 7550393 [TBL] [Abstract][Full Text] [Related]
11. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923 [TBL] [Abstract][Full Text] [Related]
12. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. Zat'ovicová M; Tarábková K; Svastová E; Gibadulinová A; Mucha V; Jakubícková L; Biesová Z; Rafajová M; Ortova Gut M; Parkkila S; Parkkila AK; Waheed A; Sly WS; Horak I; Pastorek J; Pastoreková S J Immunol Methods; 2003 Nov; 282(1-2):117-34. PubMed ID: 14604546 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441 [TBL] [Abstract][Full Text] [Related]
15. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Grabmaier K; Vissers JL; De Weijert MC; Oosterwijk-Wakka JC; Van Bokhoven A; Brakenhoff RH; Noessner E; Mulders PA; Merkx G; Figdor CG; Adema GJ; Oosterwijk E Int J Cancer; 2000 Mar; 85(6):865-70. PubMed ID: 10709109 [TBL] [Abstract][Full Text] [Related]
16. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. Chrastina A; Pastoreková S; Pastorek J Neoplasma; 2003; 50(1):13-21. PubMed ID: 12687273 [TBL] [Abstract][Full Text] [Related]
17. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Uemura H; Nakagawa Y; Yoshida K; Saga S; Yoshikawa K; Hirao Y; Oosterwijk E Br J Cancer; 1999 Oct; 81(4):741-6. PubMed ID: 10574265 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924 [TBL] [Abstract][Full Text] [Related]
19. Preliminary biological evaluation of ¹²⁵I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors. Li J; Shi L; Wang C; Zhang X; Jia L; Li X; Zhou W; Qi Y; Zhang L Nucl Med Commun; 2011 Dec; 32(12):1190-3. PubMed ID: 21968435 [TBL] [Abstract][Full Text] [Related]